Market Overview

UPDATE: Citigroup Lowers PT on Abbott Laboratories Following In-Line 2Q13 Results

Related ABT
5 Companies That Have Moved Overseas For Lower Taxes
Bet On This Top Ranked Medical Device ETF - ETF News And Commentary
Buyback Mania Inflates 2Q Earnings Growth (Fox Business)

In a report published Friday, Citigroup analyst Matthew J. Dodds reiterated a Sell rating on Abbott Laboratories (NYSE: ABT), and lowered the price target from $33.00 to $31.00.

In the report, Citigroup noted, “ABT's sales came in a bit light for the 2nd straight quarter and were in line with our forecast. Comparisons do get a bit easier in 2H but management's expectations of improvement nearly across the board still appear aggressive and likely need to be at least met in order to maintain the current premium valuation.”

Abbott Laboratories closed on Thursday at $35.70.

Posted-In: Citigroup Matthew J. DoddsAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters